Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)
Inclusion Criteria:
- Rare tumor
- metastatic disease or locally advanced disease, inoperable, with no standard
treatment
- At least 28 days since the prior treatment
- Measurable disease with at least one measurable lesion
Exclusion Criteria:
- Medullary insufficiency
- Cystitis, haemorrhagic cystitis
- Hepatic porphyria
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
For safety: NCI-CTCAE scale version 3.0
Outcome Time Frame:
42 days
Safety Issue:
Yes
Principal Investigator
Antoine ADENIS, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre Oscar Lambret
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
PALANGI-3 0804
NCT ID:
NCT01046487
Start Date:
January 2009
Completion Date:
February 2012
Related Keywords:
- Cancer
- dermatofibrosarcoma
- cylindroma
- choroid melanoma
- gastrointestinal stroma tumor
- chordoma
- ocular melanoma
- conjunctival melanoma
- malignant melanoma of the anus
- gastric melanoma
- desmoid tumor
Name | Location |
|---|
